<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02811250</url>
  </required_header>
  <id_info>
    <org_study_id>2009-556</org_study_id>
    <nct_id>NCT02811250</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiotherapy for Renal Cancers</brief_title>
  <acronym>RSR-1</acronym>
  <official_title>Stereotactic Radiotherapy for Renal Cancers: Phase I Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Stereotactic radiotherapy is a technique that allows the delivery of a high dose of radiation&#xD;
      over few fractions (3-6) with great precision. It thus allows &quot;tumor ablation&quot; and optimal&#xD;
      preservation of healthy tissues. Initially developed in small-sized (&lt;5 cm) lung cancers this&#xD;
      technique it gives results very close and or even equivalent to those of surgery.&#xD;
&#xD;
      Stereotactic radiotherapy of brain metastases of renal cancers has shown that high doses of&#xD;
      radiation allows local control in 90 to 98% of cases. A study conducted in Sweden (Wersall et&#xD;
      al.) underline the interest to develop stereotactic radiotherapy in primary renal tumors. In&#xD;
      Cleveland (USA) two phase I studies are already underway.&#xD;
&#xD;
      The investigators propose to develop a phase I study for tumors of less than 4 cm. As found&#xD;
      in lung cancers, stereotactic radiotherapy can provide a non-invasive, painless and rapid (4&#xD;
      to 5 fractions) method for the treatment of renal cancers with a high rate of local control.&#xD;
&#xD;
      The primary objective is to define the maximal tolerated dose for one fraction in&#xD;
      stereotactic mode of renal tumors ≤ 4 cm in length using an a four-step dose increase:&#xD;
&#xD;
        -  Step 1: 4 x 8 Gy.&#xD;
&#xD;
        -  Step 2: 5 x 8 Gy.&#xD;
&#xD;
        -  Step 3: 4 x 10 Gy.&#xD;
&#xD;
        -  Step 4: 4 x 12 Gy.&#xD;
&#xD;
      The patients will be followed during treatment with evaluation of acute toxicities before&#xD;
      each session, then at 15 days, 6 weeks, 3 months, 9 months, 12 months, and then every 6&#xD;
      months for a total duration of 5 years after treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 2010</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Actual">February 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of grade ≥ 4 toxicity</measure>
    <time_frame>3 months after treatment</time_frame>
    <description>The primary outcome is the occurrence of grade ≥ 4 toxicity according to CTCAE version 4 (Common Terminology Criteria for Adverse Events) during treatment and in the 3 months after end of treatment .</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Renal Cancer</condition>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 4 x 8 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 4 stereotactic radiotherapy sessions with a dose of 8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 5 x 8 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 5 stereotactic radiotherapy sessions with a dose of 8 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 4 x 10 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 4 stereotactic radiotherapy sessions with a dose of 10 Gy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stereotactic radiotherapy 4 x 12 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient receive 4 stereotactic radiotherapy sessions with a dose of 12 Gy</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 4 x 8 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 4 x 8 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 5 x 8 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 5 x 8 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 4 x 10 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 4 x 10 Gy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic radiotherapy 4 x 12 Gy</intervention_name>
    <arm_group_label>Stereotactic radiotherapy 4 x 12 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient aged over 75 years with an operable renal tumor or patient with inoperable&#xD;
             renal tumor irrespective of age, or patient with metastatic renal tumor and indication&#xD;
             for nephrectomy.&#xD;
&#xD;
          -  Histologically-confirmed Renal carcinoma less than or equal to 4 cm&#xD;
&#xD;
          -  Tumor that is visible and measureable on abdominal scanner and/or MRI (Magnetic&#xD;
             Resonance Imaging)&#xD;
&#xD;
          -  Karnofsky performance status ≥ 60%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with only one kidney and renal cancer&#xD;
&#xD;
          -  Patient not able to cooperate during treatment&#xD;
&#xD;
          -  Previous history of abdominal radiation therapy&#xD;
&#xD;
          -  Tumor having infiltrated the renal pelvis&#xD;
&#xD;
          -  Polycystic kidney disease&#xD;
&#xD;
          -  Previous history of intestinal inflammatory disease such as ulcerative colitis or&#xD;
             Crohn's disease&#xD;
&#xD;
          -  Renal insufficiency (creatinine clearance &lt;30 ml/mm evaluated by DTPA&#xD;
             (diethylenetriamine pentaacetic acid ) scintigraphy)&#xD;
&#xD;
          -  Uncontrolled hypertension (SBP(systolic blood pressure) above 160 mmHg DBP(diastolic&#xD;
             blood pressure) above 100 mmHg with antihypertensive treatment)&#xD;
&#xD;
          -  Non primary lesions (benign lesions such as angiomyolipoma, renal metastases,…)&#xD;
&#xD;
          -  Antineoplastic and/or antiangiogenic treatment in the month preceding radiotherapy&#xD;
&#xD;
          -  Progressive cancer other than renal cancer at time of inclusion with the exception of&#xD;
             in situ cervical carcinomas, basal cell carcinoma of the skin, and non-metastatic&#xD;
             prostate cancer controlled without hormone therapy&#xD;
&#xD;
          -  Participation in another ongoing study that may interfere with the present study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>75 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Service de Radiothérapie - Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie-Radiothérapie - Centre Hospitalier Lyon Sud - HCL</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 23, 2016</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal cancer</keyword>
  <keyword>Stereotactic radiotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

